# Study to Assess the Safety of Nivolumab in the Treatment of Metastatic Melanoma, Lung Cancer, Renal Cancer, Squamous Cell Carcinoma of the Head and Neck, and Chronic Hodgkin Lymphoma in Adults in Mexico

> **NCT03161613** · — · WITHDRAWN · sponsor: **Bristol-Myers Squibb**

## Conditions studied

- Multiple Indications Cancer

## Interventions

- **OTHER:** Non-Interventional

## Key facts

- **NCT ID:** NCT03161613
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** WITHDRAWN
- **Start date:** 2017-07-17
- **Primary completion:** 2019-04-01
- **Final completion:** 2019-04-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Business objectives have changed
- **Last updated:** 2022-05-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03161613

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03161613, "Study to Assess the Safety of Nivolumab in the Treatment of Metastatic Melanoma, Lung Cancer, Renal Cancer, Squamous Cell Carcinoma of the Head and Neck, and Chronic Hodgkin Lymphoma in Adults in Mexico". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03161613. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*